Journal of Clinical Oncology (JCO) Podcast

This podcast describes the recent experience of single agent rituximab as management for newly diagnosed and relapsed nodular lymphocyte predominant Hodgkin lymphoma. The podcast includes a summary of the trial and discussion of the implications of the findings that rituximab has activity in both the upfront and relapsed setting.

The mature results of a randomized comparison of S-1 versus observation in Japanese patients who have undergone a D2 resection for gastric cancer continue to show a significant survival benefit supporting the use of post-operative chemotherapy.

Children treated for medulloblastoma using reduced dose craniospinal radiation with local tumor bed boost have improved neurocognitive outcomes compared with conventional therapy, pointing to an opportunity for prevention of severe late effects by treatment modification.

The meta-analysis by Houssami and colleagues notes no recurrence benefit of breast MRI, and adds to a growing body of data demonstrating that the use of breast MRI in the non-high risk preoperative setting provides little benefit when used routinely.

Reflections on a new report describing the successful therapy of lymphomas using adoptively transferred T cells targeting EBV latent membrane proteins.

This podcast provides observations and commentary on the study by Payne and colleagues entitled 'Phase II Pilot Study of Intravenous High Dose Interferon with or without Maintenance Treatment in Melanoma at High Risk of Recurrence.'

An increased-dosage radioimmunotherapy for upfront treatment of follicular lymphoma achieves excellent results, raising questions on the best choice of treatment in this disease.

This podcast describes the recent experience of high dose cytarabine induction in patients with acute myeloid leukemia (AML), as reported in the EORTCGIMEMA AML-12 trial. The podcast includes a summary of the trial and discussion of the implications of the finding that high dose cytarabine induction improves outcomes in younger patients with AML.

MRI done prior to surgery can be useful in determining the long-term outcomes after surgical resection in patients with rectal cancer.

The study by Kapoor et al supports reporting outcome of clinical trials using more stringent uniform response criteria.

This podcast reviews outcomes for elderly patients with HODGKIN lymphoma at diagnosis and at the time of relapse.

Sentinel node biopsy should be performed for melanomas greater than or equal to 0.75mm in thickness but not for melanomas less than 0.75mm in thickness.

This podcast discusses Neben and colleagues' paper on FISH findings and smoldering myeloma.

This JCO Podcast comments on the JCO article, "Interim Cosmetic and Toxicity Results From Rapid: A Randomized Trial Of Accelerated Partial Breast Irradiation Using 3D Conformal External Beam Radiation Therapy" by Ivo A. Olivotto, et al.

Before we can use MRD as a guide of post-remission therapy in AML, we have to standardize our methods for MRD quantification and agree on the definition of MRD-positive versus MRD-negative patients.

ACRIN 6668/RTOG 0235 demonstrates that a post chemoradiotherapy PET scan for locoregionally advanced non-small cell lung cancer can be used as an early indicator for long-term outcome.

Added to the complexity of the widening variety of vaccines that are in current clinical trial for human cancers, and the increasing sophistication of our tools for assessment of the immune response underlying these vaccine interventions, this podcast discusses the elements of trial design and reporting in relation to the trial EORTC 18961.

Lenalidomide is a promising agent for the treatment of mantle cell lymphoma.

The results of CALGB 50202 reported by Rubenstein and colleagues demonstrate the feasibility, safety and efficacy of the MT-R induction and EA consolidation regimens in newly diagnosed PCNSL patients.

This podcast reviews the biology and treatment of relapse of acute myeloid leukemia following hematopoietic transplantation.

The ability of an advance care planning discussion to affect end-of-life decisions is tested in a randomized, controlled trial of patients with advanced cancer.

The AVAPERL trial reveals a significant improvement in progression-free survival with the combination of pemetrexed/bevacizumab compared with bevacizumab alone as maintenance therapy for advanced non- small-cell lung cancer, but the clinically relevant endpoint remains overall survival.

This JCO Podcast provides observations and commentary on the JCO article "Osteonecrosis of the Jaw and Oral Health-Related Quality of Life After Adjuvant Zoledronic Acid: An Adjuvant Zoledronic Acid to Reduce Recurrence Trial Subprotocol (BIG01/04)" by Emma Rathbone et al.

Minimal residual disease predicts outcomes in myeloma.

This podcast provides an overview and commentary on Amant et al.'s study of breast cancer diagnosed during pregnancy.